(PHR) Phreesia - Ratings and Ratios
Scheduling Software, Registration Tools, Payment Processing, Network Content
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 53.1% |
| Value at Risk 5%th | 82.1% |
| Relative Tail Risk | -5.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -15.75 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.523 |
| Beta | 1.055 |
| Beta Downside | 1.009 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.62% |
| Mean DD | 34.61% |
| Median DD | 36.79% |
Description: PHR Phreesia November 13, 2025
Phreesia, Inc. (NYSE: PHR) operates a SaaS-based platform that digitizes front-office workflows for U.S. and Canadian healthcare providers. Its product suite spans online appointment scheduling, patient self-registration, insurance verification, point-of-sale and post-visit payment collection, plus content delivery through mobile apps, self-service tablets, web dashboards and on-site kiosks. The company serves a broad client base-from single-specialty practices to large health systems and life-science firms-leveraging a unified platform to streamline intake, improve revenue cycle efficiency, and enhance patient engagement.
Key recent metrics underscore the business’s growth trajectory: FY 2023 revenue reached $215 million, up 22 % YoY, driven largely by a 35 % increase in subscription ARR from new health-system contracts; gross margin improved to 78 % as the mix shifted toward higher-margin SaaS subscriptions; and net dollar retention exceeded 115 %, reflecting strong upsell and cross-sell activity. Primary economic drivers include accelerating adoption of digital front-end solutions amid rising healthcare spending (projected CAGR 5.5 % through 2028) and payer pressure to reduce administrative costs, while sector-wide trends such as telehealth expansion and value-based care reimbursement models further boost demand for automated intake and revenue-cycle tools.
For a deeper quantitative assessment, you may want to explore the ValueRay platform’s detailed financial models for PHR.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (-24.1m TTM) > 0 and > 6% of Revenue (6% = 27.0m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 15.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.13% (prev 20.24%; Δ 5.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 51.7m > Net Income -24.1m (YES >=105%, WARN >=100%) |
| Net Debt (-93.5m) to EBITDA (6.85m) ratio: -13.66 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (59.3m) change vs 12m ago 3.06% (target <= -2.0% for YES) |
| Gross Margin 72.52% (prev 60.93%; Δ 11.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 116.7% (prev 107.7%; Δ 9.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.44 (EBITDA TTM 6.85m / Interest Expense TTM 2.06m) >= 6 (WARN >= 3) |
Altman Z'' -12.54
| (A) 0.29 = (Total Current Assets 222.6m - Total Current Liabilities 105.1m) / Total Assets 408.6m |
| (B) -1.97 = Retained Earnings (Balance) -804.8m / Total Assets 408.6m |
| warn (B) unusual magnitude: -1.97 — check mapping/units |
| (C) -0.06 = EBIT TTM -21.5m / Avg Total Assets 385.4m |
| (D) -7.27 = Book Value of Equity -804.0m / Total Liabilities 110.6m |
| Total Rating: -12.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.54
| 1. Piotroski 6.0pt |
| 2. FCF Yield 3.11% |
| 3. FCF Margin 7.76% |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda -13.66 |
| 6. ROIC - WACC (= -20.32)% |
| 7. RoE -8.75% |
| 8. Rev. Trend 98.83% |
| 9. EPS Trend 91.89% |
What is the price of PHR shares?
Over the past week, the price has changed by +2.19%, over one month by -12.47%, over three months by -37.05% and over the past year by -2.57%.
Is PHR a buy, sell or hold?
- Strong Buy: 10
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.6 | 63.8% |
| Analysts Target Price | 33.6 | 63.8% |
| ValueRay Target Price | 19.4 | -5.6% |
PHR Fundamental Data Overview November 26, 2025
P/E Forward = 333.3333
P/S = 2.7021
P/B = 4.0313
Beta = 0.635
Revenue TTM = 449.7m USD
EBIT TTM = -21.5m USD
EBITDA TTM = 6.85m USD
Long Term Debt = 4.58m USD (from longTermDebt, last quarter)
Short Term Debt = 7.10m USD (from shortLongTermDebt, last quarter)
Debt = 4.75m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -93.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.12b USD (1.22b + Debt 4.75m - CCE 98.3m)
Interest Coverage Ratio = -10.44 (Ebit TTM -21.5m / Interest Expense TTM 2.06m)
FCF Yield = 3.11% (FCF TTM 34.9m / Enterprise Value 1.12b)
FCF Margin = 7.76% (FCF TTM 34.9m / Revenue TTM 449.7m)
Net Margin = -5.35% (Net Income TTM -24.1m / Revenue TTM 449.7m)
Gross Margin = 72.52% ((Revenue TTM 449.7m - Cost of Revenue TTM 123.6m) / Revenue TTM)
Gross Margin QoQ = 85.16% (prev 67.17%)
Tobins Q-Ratio = 2.74 (Enterprise Value 1.12b / Total Assets 408.6m)
Interest Expense / Debt = 9.15% (Interest Expense 435.0k / Debt 4.75m)
Taxrate = -100.0% (out of range, set to none) (563.0k / -563.0k)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.12 (Total Current Assets 222.6m / Total Current Liabilities 105.1m)
Debt / Equity = 0.02 (Debt 4.75m / totalStockholderEquity, last quarter 298.0m)
Debt / EBITDA = -13.66 (Net Debt -93.5m / EBITDA 6.85m)
Debt / FCF = -2.68 (Net Debt -93.5m / FCF TTM 34.9m)
Total Stockholder Equity = 274.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.89% (Net Income -24.1m / Total Assets 408.6m)
RoE = -8.75% (Net Income TTM -24.1m / Total Stockholder Equity 274.9m)
RoCE = -7.68% (EBIT -21.5m / Capital Employed (Equity 274.9m + L.T.Debt 4.58m))
RoIC = -10.46% (negative operating profit) (EBIT -21.5m / (Assets 408.6m - Curr.Liab 105.1m - Cash 98.3m))
WACC = 9.86% (E(1.22b)/V(1.22b) * Re(9.90%) + (debt cost/tax rate unavailable))
Discount Rate = 9.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.57%
[DCF Debug] Terminal Value 62.56% ; FCFE base≈34.9m ; Y1≈22.9m ; Y5≈10.5m
Fair Price DCF = 2.60 (DCF Value 155.9m / Shares Outstanding 59.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 91.89 | EPS CAGR: 114.4% | SUE: 0.01 | # QB: 0
Revenue Correlation: 98.83 | Revenue CAGR: 21.83% | SUE: 0.37 | # QB: 0
Additional Sources for PHR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle